The systemic lupus erythematosus (SLE) market in the United States is largely genericized and off-label. With the exception of Benlysta (IV)—which launched in 2011—no new drug has been approved for this indication in almost 60 years. Several biologics are in late-stage development for moderate to severe SLE, including agents targeting a previously underserved subpopulation of SLE patients, those with active lupus nephritis. Systemic Lupus Erythematosus ¦Access & Reimbursement ¦US examines the prescribing and reimbursement environment for Benlysta (IV) and emerging SLE agents in the United States, according to surveyed rheumatologists and managed care organization (MCO) pharmacy directors and medical directors. This content explores how physicians and payers perceive current and emerging SLE therapies and the reimbursement dynamics that will promote or restrict market access of these agents.


Related Reports

Systemic Lupus Erythematosus - Landscape & Forecast - Disease Landscape & Forecast

Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course,...

View Details

Systemic Lupus Erythematosus | Disease Landscape and Forecast | G7 | 2020

Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be hig...

View Details

Systemic Lupus Erythematosus - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US) 2021

MARKET OUTLOOK Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. SLE symptoms range from general malaise to serio...

View Details

Systemic Lupus Erythematosus - Access & Reimbursement - Detailed, Expanded Analysis (US)

The systemic lupus erythematosus (SLE) therapy market in the United States is largely genericized and off-label. With the exception of GlaxoSmithKline’s Benlysta—which launched in 2011&...

View Details